Search results for "Precision medicine."

showing 10 items of 211 documents

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.

2013

Objective Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti–tumor necrosis factor α (anti-TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease-modifying antirheumatic drugs. Methods Patients were identified from 15 outpatient clinics of university hospitals and hospitals in Italy taking part in the Gruppo Italiano di Studio sulle Early Arthritis network. Disease Activity Score in 28 joints (DAS28), body mass index (BMI; categorized …

MaleSettore MED/16 - REUMATOLOGIAArthritisGastroenterologyReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidRheumatoidMonoclonalReceptorsMedicineOutpatient clinicLongitudinal StudiesRegistriesPrecision Medicineskin and connective tissue diseasesHumanizedRemission InductionAntibodies MonoclonalIndividualized MedicineMiddle AgedTreatment OutcomeRheumatoid arthritisAntirheumatic AgentsFemaleDrugmedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyAdalimumab; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Longitudinal Studies; Male; Middle Aged; Obesity; Precision Medicine; Receptors Tumor Necrosis Factor; Registries; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alphaAntibodies Monoclonal HumanizedAntibodiesDose-Response RelationshipRheumatologyInternal medicineAdalimumabHumansObesityRisk factorAgedDose-Response Relationship Drugbusiness.industryTumor Necrosis Factor-alphaArthritisAdalimumabmedicine.diseaseInfliximabRheumatologyInfliximabAged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Female; Humans; Immunoglobulin G; Individualized Medicine; Longitudinal Studies; Male; Middle Aged; Obesity; Receptors Tumor Necrosis Factor; Registries; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alphaImmunoglobulin GImmunologybusinessTumor Necrosis FactorArthritis careresearch
researchProduct

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

2020

BACKGROUND: The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal function in patients with acute heart failure and renal dysfunction at presentation. METHODS: This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-gui…

Maleendocrine system diseasesPREDICTIONmedicine.medical_treatmentUrine030204 cardiovascular system & hematologyKidney Function TestsCONGESTIONBiomarker guided-therapy0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsFurosemideNatriuretic peptideMedicineRenal Insufficiency030212 general & internal medicinePrecision MedicineANTIGEN CARBOHYDRATE 125Aged 80 and overFurosemideGeneral MedicineDiuretic treatmentEUROPEAN-SOCIETYClinical trialFemaleTRIALmedicine.drugmedicine.medical_specialtyRenal failureSTRATEGIESmedicine.drug_classUrologyRenal function03 medical and health sciencesHumansIn patientAgedHeart FailureSERUM CREATININENATRIURETIC PEPTIDEbusiness.industryMORTALITYMembrane ProteinsAcute heart failuremedicine.diseaseClinical trialCarbohydrate antigen 125CA-125 AntigenHeart failureDiuretic treatmentDiureticbusinessCARDIORENAL SYNDROME
researchProduct

Individualized Comprehensive Lifestyle Intervention in Patients Undergoing Chemotherapy with Curative or Palliative Intent: Who Participates?

2015

Objective Knowledge about determinants of participation in lifestyle interventions in cancer patients undergoing chemotherapy, particularly with palliative intent, remains poor. The objective of the present study was to identify determinants of participating in a 12 month individualized, comprehensive lifestyle intervention, focusing on diet, physical activity, mental stress and smoking cessation, in cancer patients receiving chemotherapy with curative or palliative intent. The secondary objective was to identify participation determinants 4 months into the study. Methods Newly diagnosed cancer patients starting chemotherapy at the cancer center in Kristiansand/Norway (during a 16 month inc…

Malemedicine.medical_specialtyPalliative caremedicine.medical_treatmentlcsh:MedicineAntineoplastic AgentsBreast NeoplasmsBreast cancerInternal medicinemedicineHumansPrecision Medicinelcsh:ScienceLife StyleSocioeconomic statusAgedChemotherapyMultidisciplinarybusiness.industryPalliative Carelcsh:RProstatic NeoplasmsCancerMiddle Agedmedicine.diseaseCombined Modality TherapyPhysical therapySmoking cessationMarital statusFemaleSmoking Cessationlcsh:QColorectal NeoplasmsbusinessBody mass indexResearch ArticlePLOS ONE
researchProduct

Introducing sexual dysfunction in mental care.

2020

Introduction: People with any psychiatric disorder tend to have difficulties in responding sexually. However,sexual dysfunction (SD) is usually under-recognized, even the tightly hormonal and neuro...

Malemedicine.medical_specialtyPsychotropic Drugsbusiness.industryMental DisordersGeneral Medicine030204 cardiovascular system & hematology03 medical and health sciencesSexual Dysfunction Physiological0302 clinical medicineSexual dysfunction030220 oncology & carcinogenesisQuality of LifeMedicineHumansPharmacology (medical)FemaleSexual Dysfunctions Psychologicalmedicine.symptomPrecision MedicinebusinessAdverse effectPsychiatryExpert opinion on drug safety
researchProduct

Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the rea…

2022

Abstract Background Tobacco smoking has been associated with suicide, impulsivity and depression in non-clinical populations with differences across sexes. Objective To determine the role of tobacco smoking in Treatment-Resistant Depression (TRD) according to sex in a precision-medicine approach. Method The FACE-TRD cohort is a national cohort of TRD patients recruited in 13 resistant depression expert centers between 2014 and 2021 and followed-up at 6 months. A standardized one-day long comprehensive battery was carried out, including trained-clinician and patient-reported outcomes, and patients were reevaluated at 6 months on their smoking and psychiatric hospitalization outcomes. Results…

Malemedicine.medical_treatmentMESH: Tobacco SmokingSuicide AttemptedtobaccoMESH: NicotineCohort StudiesDepressive Disorder Treatment-Resistantchemistry.chemical_compoundSurveys and QuestionnairesMedicinePrecision MedicineVareniclineMESH: Cohort StudiesDepression (differential diagnoses)health care economics and organizationseducation.field_of_studypublic mental healthMESH: Middle AgedMESH: Suicidal Ideationpublic healthMiddle AgedMESH: Smoking CessationpsychiatryCohortdepressionMESH: Suicide AttemptedFemalemental healthNicotinemedicine.medical_specialtyPopulationeducationMESH: Precision MedicinesmokingSuicidal IdeationMESH: Depressive Disorder Treatment-ResistantSex FactorsMESH: Sex FactorsTobacco SmokingHumansMESH: Surveys and QuestionnaireseducationPsychiatryBiological PsychiatryPharmacologyMESH: HumansSuicide attemptbusiness.industryOdds ratiomedicine.diseaseMESH: Maleschizophreniachemistry[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthSmoking cessationSmoking CessationbusinessTreatment-resistant depressionMESH: Female
researchProduct

Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells.

2020

Models MolecularProto-Oncogene Proteins B-rafProtein ConformationMutantMutation MissenseDermatologyInhibitory Concentration 50Structure-Activity RelationshipCell Line TumormedicineHumansPoint MutationMolecular Targeted TherapyPrecision MedicineMelanomaProtein Kinase InhibitorsDose-Response Relationship Drugbusiness.industryMelanomaDrug Repositioningmedicine.diseaseNeoplasm ProteinsBRAF V600EMolecular Docking SimulationAmino Acid SubstitutionDrug DesignCancer researchIdentification (biology)Drug Screening Assays AntitumorbusinessJournal of the American Academy of Dermatology
researchProduct

In the literature: August 2018.

2018

Pancreatic ductal adenocarcinoma (PDAC) is characterised by a very poor prognosis. Despite some minor therapeutic advances, median overall survival of patients with metastatic disease ranges from 6 to 11 months. Even for those who undergo potential curative surgery, expected median survival is below 27 months. Current treatment for both localised and metastatic disease is often based on unspecific characteristics, such as performance status and comorbidities. As many patients with PDAC are chemorefractory, there is an unmet clinical need to define responsiveness. Moreover, precision medicine approaches for pancreatic cancer are challenging. In an article recently published in Cancer Discove…

OncologyCancer Researchmedicine.medical_specialtyChemotherapyPerformance statusbusiness.industrymedicine.medical_treatmentConcordanceCancerDiseasePrecision medicinemedicine.diseaseGemcitabineOncologyInternal medicinePancreatic cancermedicinebusinessmedicine.drugESMO open
researchProduct

In the literature: April 2018

2018

The most important aim of precision medicine is the selection of the best treatment for each individual patient. To achieve this objective, the analysis of the molecular changes that can occur due to tumour heterogeneity or after anticancer treatment is fundamental. A dynamical study of the disease could lead to the identification of specific targets, which need to be inhibited at time of tumour progression. By using high-throughput sequencing, it is possible to identify a very limited number of somatic mutations that can be exploited for cancer treatment and drug development. However, the ability to predict response to targeted agents needs to be further improved. To do this, parallel stud…

OncologyCancer Researchmedicine.medical_specialtyPathologyTumour heterogeneitybusiness.industryConcordanceliteratureDiseaseNewsPrecision medicineTranscriptomeClinical trialOncologyDrug developmentInternal medicineCancer cellmedicine1506businessESMO Open
researchProduct

How to optimize HCV therapy in genotype 1 patients: predictors of response.

2013

The advent of triple therapy (TT) with first-generation protease inhibitors boceprevir (BOC) and telaprevir (TVR) in addition to pegylated interferon and ribavirin (PEG-IFN/RBV) has resulted in a significant improvement in the sustained virological response (SVR) rate and potentially in life years gained compared to dual therapy (DT), when treating naive or treatment-experienced patients with genotype 1 (G1) chronic hepatitis C (CHC). This benefit is partly offset by the increased complexity of treatment, and the increased costs and risks of therapy, making it necessary to optimize the indications for TT. Naive patients with mild fibrosis and the IL28B CC polymorphism and/or with a rapid vi…

OncologyLiver Cirrhosismedicine.medical_specialtyGenotypeHepacivirusAntiviral AgentsTelaprevirchemistry.chemical_compoundPharmacotherapyPegylated interferonRisk FactorsInternal medicineBoceprevirmedicineHumansPrecision MedicineHepatologybusiness.industryRibavirinInterleukinsPatient SelectionHepatitis CHepatitis C ChronicViral Loadmedicine.diseaseTreatment OutcomechemistryPharmacogeneticsImmunologyHCVDrug Therapy CombinationInterferonsbusinessViral loadPharmacogeneticsmedicine.drugLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma

2014

BACKGROUND: Risk classification and treatment stratification for cancer patients is restricted by our incomplete picture of the complex and unknown interactions between the patient's organism and tumor tissues (transformed cells supported by tumor stroma). Moreover, all clinical factors and laboratory studies used to indicate treatment effectiveness and outcomes are by their nature a simplification of the biological system of cancer, and cannot yet incorporate all possible prognostic indicators. METHODS: A multiparametric analysis on 184 tumor cylinders was performed. To highlight the benefit of integrating digitized medical imaging into this field, we present the results of computational s…

OncologyRiskmedicine.medical_specialtyStromal cellBiologyBioinformaticsExtracellular matrixNeuroblastomaInternal medicineNeuroblastomaNeoplasmsmedicineExtracellularCluster AnalysisHumansIn patientPrecision MedicineChildCell Line TransformedGlycosaminoglycansMultiparametric AnalysisCancerComputational BiologyInfantModels Theoreticalmedicine.diseasePrognosisExtracellular MatrixChild PreschoolPediatrics Perinatology and Child HealthCancer cellStromal CellsAlgorithms
researchProduct